WO2004062635A1 - Compositions for skin lightening comprising bis-pantoyl-cystamine - Google Patents

Compositions for skin lightening comprising bis-pantoyl-cystamine Download PDF

Info

Publication number
WO2004062635A1
WO2004062635A1 PCT/EP2003/010702 EP0310702W WO2004062635A1 WO 2004062635 A1 WO2004062635 A1 WO 2004062635A1 EP 0310702 W EP0310702 W EP 0310702W WO 2004062635 A1 WO2004062635 A1 WO 2004062635A1
Authority
WO
WIPO (PCT)
Prior art keywords
bis
cystamine
pantoyl
derivatives
skin
Prior art date
Application number
PCT/EP2003/010702
Other languages
French (fr)
Inventor
David Carl Burdick
Philippe Emmanuel Maillan
Jochen Klock
Horst Westenfelder
Volker Schehlmann
Christine Saecker
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Priority to AU2003267413A priority Critical patent/AU2003267413A1/en
Publication of WO2004062635A1 publication Critical patent/WO2004062635A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur

Definitions

  • the present invention relates to compositions for skin lightening comprising bis-pantoyl- cystamine or derivatives thereof. More particularly, the present invention relates to topical compositions comprising bis-pantoyl-cystamine or derivatives thereof for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin.
  • the present invention relates to the use of bis-pantoyl- cystamine or a derivative thereof in the manufacture of a topical composition for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin and to a method of lightening the skin, treating hyperpigmented skin disorders and preventing tanning of the skin which comprises topically administering bis-pantoyl-cystamine or a derivative thereof to the inflicted parts of the skin of a person in need of such treatment.
  • Skin lightening has been of concern to human beings for many years.
  • the ability to remove hyper pigmentation, such as found in age spots, freckles or aging skin generally, is of interest to individuals to minimize skin blotchiness or desiring a uniform skin tone.
  • Skin lightening in humans is also desired to lighten the natural color of their skin or to prevent of tanning after environmental factors like UV and leads to a more even skin tone.
  • melanin a biopolymer pigment manufactured by special dendritic cells known as melanocytes residing mostly between the basal cells of the epidermis.
  • melanocytes produce secretory granules, melanosomes, which produce the desired melanin.
  • Melanogenesis occurs within the melanosome, and the melanin is later distributed to keratinocytes via the melanocytes dendrites and leads to a more or less pronounced tan or brown skin color.
  • the biochemical process is a cascade of biosynthesis where the key enzyme is called tyrosinase and triggers several steps in the formation of melanin from tyrosine.
  • Melanin is the end product of an oxidative process in which tyrosine is converted with the aid of the enzyme tyrosinase via 3,4-dihydroxyphenylanlanine (dopa), dopaquinone, leucodopacrome, dopacrome, 5,6-dihydroxyindol and indole-5,6-quinone to give, finally, melanin.
  • dopa 3,4-dihydroxyphenylanlanine
  • dopaquinone dopaquinone
  • leucodopacrome dopacrome
  • dopacrome 5,6-dihydroxyindol
  • indole-5,6-quinone to give, finally, melanin.
  • Exposure to sunlight or other UV radiation can stimulate the melanocytes to produce more melanin, hence the so-called “tanning" reaction. Melanin production can also increase in response to hormone fluctuations associated with aging, child bearing or the use of birth-control pills.
  • Normal pigmentation of the skin surface is uniform. Localized, excessive pigmentation can occur and such colorization is collectively referred to as hyper pigmentation. Hyper pigmentation encompasses a wide array of afflictions, all of which are accompanied by increased melanin production.
  • Hyper pigmentation of the human skin may include skin blemishes or disorders including freckles, senile lentigo, liver spots, melasma, brown or age spots, sunburn pigmentation, post-inflammatory hyper pigmentation due to abrasion, burns, wounds, insect bites, dermatitis, and other similar small, fixed pigmented lesions.
  • the present invention thus comprises topical compositions, i.e. compositions for cosmetic as well as for dermatological, i.e., pharmaceutical, use which contain the active ingredient, bis-pantoyl-cystamine or a derivative thereof, in a vehicle that is conventionally used in cosmetic or topical dermatological compositions.
  • the amount of bis-pantoyl-cystamine or derivative thereof in such compositions is about 0.005 % by weight to about 8.0 % by weight, preferably about 0.05% by weight to about 5.0 % by weight based on bis-pantoyl- cystamine and the total weight of the composition, respectively. .
  • the treatment may extend to a period up to several monthsln general, a treatment for the duration of 6-8 weekswill suffice to achieve a substantial lightening effect.
  • the compound bis-pantoyl-cystamine (by systematical name : N,N'-(dithio-2,l- ethanediyl)bis(2,4-dihydrox-3,3-dimethyl) butanamide) which has the formula
  • bis-pantoyl-cystamine may exist in 3 isomeric forms with RR, RS and SS configurations.
  • the isomer with RR configuration is known and has been described in the literature ( Boxer at al, J. Biol Chem., 1955, 217,541 Shimizu et al Chem Pharm Bull, 1970, 18, 838 .)
  • the RR/SS diastereomeric pair and the RS (meso) isomer, and mixtures of RR, SS, RR/SS and RS are new and, as such, are also an object of the present invention.
  • the new isomers and mixtures are preferred. Particularly preferred are the RR/SS diastereomeric pair, and the mixture composed of RR, RS, and SS isomers in a molar ratio of about 25:50:25 to about 30:40:30. They possess unexpected advantageous properties for manufacture, handling, and use.
  • the substances described are conveniently prepared by reaction of pantolactone with cystamine.
  • the RR isomer results which in pure form is found to be a very viscous oil.
  • S-pantolactone is used, the SS isomer results, which as the pure isomer is also a very viscous oil.
  • racemic pantolactone When racemic pantolactone is used, there results a mixture composed of RR, RS, and SS isomers in a molar ratio of 25:50:25. Unexpectedly, this mixture can easily be crystallized to a white solid which can be further purified by recrystallization, e.g., from ethyl acetate or water. Such purification may result in a change of the RR, RS, and SS isomer molar ratio to about 30:40:30. For the purposes of the present invention, the preferred molar ratio in terms of the RS (meso) to RR/SS ratio is in the range from about 50:50 to about 30:70.
  • Cosmetic products require the highest standard of purity and safety because of contact to human skin, hair, and mucous membranes. Customers are particularly sensitive to color and odor of such products. Thus purification to the highest quality of this type products is essential. And ease of purification an advantage to manufacturing.
  • the RR or SS isomers can be used as hair care products provided specialized methods of purification are employed.
  • the mixture of RR/SS and RS meso isomers offer an advantage is being easily purified by conventional chemical process techniques such as crystallization. Accordingly, for the purposes of the present invention the use of the mixture of RR/SS and RS meso isomers, and derivatives thereof, is preferred.
  • derivative denotes any compound that is obtained from bis- pantoyl-cystamine by modification of the hydroxy groups contained therein, particularly the terminal hydroxy groups, and which, while possessing the same or higher degree of lipophilicity than bis-pantoyl-cystamine exerts a similar activity as bis-pantoyl-cystamine.
  • the making of lipophilic derivatives is a well known method by the person skilled in the art to achieve better skin delivery of a topically applied active ingredient.
  • acylates particularly acylates formed with aliphatic, aromatic or araliphatic carboxylic acids containing 2-20 carbon atoms, which may be saturated or unsaturated, and maybe substituted by, e.g. hydroxy groups, such as the mono- or di-acetate, propionate, butyrate, caproate, caprylate, caprate, laurate, myristate, lactate, 2- hydroxycaprylate, 2-hydroxycaprate, 2-hydroxylaurate, 2-hydroxymyristate, di-2-heptyl- undecanoate, and salicylate.
  • acylates derived from unsaturated carboxylic acids are oleates and linoleates.
  • compositions of the present invention can, e.g., be provided in the form of a lotion, a thickened lotion, a gel, a cream, a milk, a cleansing composition, an ointment, a powder or a solid tube stick and may optionally be packaged as an aerosol and may be provided in the form of a mousse, foam or a spray.
  • emulsions may be in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or microemulsion (in particular of O/W or W/O type, O/W/O or W/O/W-type), such as a cream or a milk, a vesicular dispersion, in the form of an ointment, a gel, a solid tube stick or an aerosol mousse.
  • the emulsions can also contain anionic, nonionic, cationic or amphoteric surfactants.
  • compositions of the invention also contain adjuvants and additives, which are conventionally used in cosmetic or dermatological compositions, such as preservatives/ antioxidants, fatty substances/ oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, additional sunscreens, antifoaming agents, moisturizers, skin penetration enhancers, vitamins, desquamation actives, skin soothing actives, fragrances, surfactants, cleansing agents, fillers, sequestering agents, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorants, pigments or nanopigments, in particular UV screening agents suitable for providing a photoprotective effect by physically blocking out ultraviolet radiation, conventional skin lightening agents, or any other ingredients usually formulated into cosmetics, in particular for the production of skin lightening compositions, sunscreen compositions and anti- aging compositions.
  • adjuvants and additives which are conventionally used in cosmetic or dermatological compositions, such
  • bis-pantoyl-cystamine or derivatives thereof is used in combination with one or more agents selected from UV screening agents, vitamin A or derivatives thereof, ascorbic acid or ascorbic acid derivatives, vitamin E or . derivatives thereof, a vitamin from the B complex, panthenol, phytantriol, bisabolol or derivatives thereof, Kojic acid or derivatives thereof, Arbutin or derivatives thereof, Hydroquinone or derivatives thereof, Genistein or derivatives thereof, Epigallocatechin Gallate or derivatives thereof, and Resveratrol or derivatives thereof, Phyllanthus Emblica fruit extract, Leucocyte extract, Bearberry extract, Licorice extract and Mulberry extract .
  • UV screening agent means a compound or composition that absorbs UV radiation in the range of about 320 nm to about 400 nm (UV-A) or in the range of about 280 nm to about 320 nm (UV-B).
  • UV filters can be organic or inorganic.
  • Organic sunscreens include dibenzoylmethane derivatives such as butyl methoxydibenzoylmethane (PARSOL 1789), benzylidene-cyanoacetates such as 4-mefhoxy-benzylidene-cyanoacetic acid n-hexyl ester, triazine derivatives such as 4,4'-(6-(bis(2-ethyl-hexyl)-amino)-s- triazine-2,4-diyl)-diresorcinol, anilinomethylene derivatives such as 2-(4-ethoxy-anilino- methylene)-propanedioic acid diethyl ester, camphor derivatives sich as 4-methyl benzylidene camphor (PARSOL 5000) and terephtalylidene-3,3'-dicamphor-10,10'-disul- fonic acid, benzimidazol derivatives such as 2,2'-( l,4
  • the UV-A filter is selected from the group consisting of PARSOL 1789, 4,4'-(6-(bis(2- ethyl-hexyl)-amino)-s-triazine-2,4-diyl)-diresorcinol (Triazin), 2-(4-ethoxy- anilinomethylene)-propanedioic acid diethyl ester, and mixtures thereof, PARSOL MCX or PARSOL SLX.
  • a 0, 1 or 2
  • R 1 is hydrogen, a saturated or unsaturated C ⁇ -C 3 ohydrocarbon group or a trimethylsilyloxy group; and Z is an amino substituted hydroxybenzophenone of the formula wherein
  • R 3 and R 4 independently are hydrogen, C ⁇ -C 20 alkyl, C 2 -C 2 oalkenyl, C 3 -C ⁇ 0 cycloalkyl or C 3 -C ⁇ ocycloalkenyl or R and R , together with the nitrogen atom they are bound to, form a 5 to 6 membered ring;
  • X is -O- or -NR 5 - wherein R 5 is hydrogen, C ⁇ -C 2 oalkyl, C 2 -C 2 oalkenyl, C 3 -C 10 cycloalkyl or C 3 -C ⁇ ocycloalkenyl; and
  • Y is a divalent C 3 -C ⁇ 2 alkylene or alkenylene chain; and, optionally, a unit of the formula
  • b 0, 1, 2, 3;
  • R 2 is hydrogen, a saturated or unsaturated CrC 30 hydrocarbon group or a trimethylsilyloxy group
  • R and R" are identical or different electron-withdrawing groups, or one of R 1 and R is hydrogen and the other of R and R is an electron-withdrawing group;
  • R 3 , R 4 , R 5 , are R 6 are, independently, hydrogen, alkyl or aryl;
  • R 3 and R 5 and/ or R 4 , and R 6 taken together with the carbon atoms to which they are attached, may form a 5 or 6 membered ring which optionally is substituted with one to four alkyl or alkoxy groups;
  • X is a moiety R 7 , when m is 1; and is alkylene or poly(oxyalkylene) when m is 2; and
  • R 7 is hydrogen, alkyl, alkoxyalkyl or aryl; and
  • R 1 and R are, independently from each other, hydrogen; halogen; hydroxy; ( - C 2 o)-alkyl; (C 2 -C 2 o)-alkenyl; or (CrC 2 o)-alkoxy;
  • X is oxygen or an imino group, optionally substituted with R 1 ;
  • R 3 and R 4 are, independently from each other, cyano; -COOR 5 ; -COR 6 ; -CONH 2 ; -CONHR 7 ; or -CONR 8 R 9 ;
  • R 5 , R 6 , R 7 , R 8 and R 9 are, independently from each other, hydrogen; (C ⁇ -C 2 o)-alkyl, wherein one or more methylene groups are optionally replaced by one or more oxygens;
  • C 2 -C 2 o)-alkenyl optionally substituted by tri-(C ⁇ -C 5 )-alkyl
  • a safe and effective amount of the organic sunscreen active is used, typically from about 1 wt.-% to about 20 wt.-%, more typically from about 2 wt.-% to about 10 wt.-%.
  • Inorganic sunscreens useful herein include the following metallic oxides; titanium dioxide having an average primary particle size of from about 15 nm to about 100 am, zinc oxide having an average primary particle size of from about 15 nm to about 150 mu, zirconium oxide having an average primary particle size of from about 15 nm to about 150 nm, iron oxide having an average primary particle size of from about 15 nm to about 500 nm, and mixtures thereof.
  • the inorganic sunscreens are present in the amount of from about 0.1 wt.-% to about 20 wt.-%, preferably from about 0.5 wt.-% to about 10 wt.-%, more preferably from about lwt.-% to about 5 wt.-%.
  • Vitamin A acetate or palmitate which may be present in the skin care products in an amount from about 0.01 wt.-% to about 1.00 wt.-%.
  • the term ascorbic acid derivative for use in accordance with the present invention may by any non-toxic, non skin-irritating water-soluble or oil-soluble ascorbic acid derivative.
  • oil soluble derivatives are ascorbyl palmitate, ascorbyl tetraisopalmitate, ascorbyl linoleate, ascorbyl octanoate.
  • Preferred are water soluble ascorbyl derivatives such as sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl glycoside.
  • the amount of ascorbic acid derivative in the skin care product for use in accordance with the present invention is suitably in the range from about 0.1 wt.-% to about 5 wt.-%.
  • a vitamin E derivative for use in the present invention is tocopheryl acetate.
  • Tocopheryl acetate may be present in the skin care products in an amount from about 0.05 wt.-% to about 5 wt.-%.
  • Another vitamine E derivative of interest is tocopheryl linoleate.
  • Tocopheryl linoleate may be present in the skin care composition in an amount from about 0.05 wt.-% to about 5 wt-%.
  • vitamins from the B complex for use in the present invention are vitamin B 3 , B 6 and biotin.
  • Vitamin B 3 ma be present in the skin care products in an amount from about 0.01 wt.-% to about 1.00 wt.-%.
  • Vitamin B 6 maybe present in the skin care products in an amount from about 0.01 wt-% to about 1.00 wt.-%.
  • Biotin ma be present in the skin care products in an amount from about 0.001 wt.-% to about 0.5 wt.-%.
  • Panthenol may be present in the skin care products in an amount from about 0.05 wt-% to about 5.00 wt.-%.
  • Phytantriol may be present in the skin care products in an amount from about 0.01 wt.-% to about 2.5 wt.-%.
  • Bisabolol may be present in the skin care products in an amount from about 0.05 wt.-% to about 5.00 wt-%.
  • Further skin lightening agent which may be used in the present invention in combination with bis-pantoyl-cystamine are Kojic acid or derivatives thereof, which may be present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 5 wt-%;
  • Arbutin or derivatives thereof which maybe present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 5 wt-%;
  • Hydroquinone or derivatives thereof which may be present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 2 wt-%;
  • Phyllanthus Emblica fruit extract (trade name: Emblica ), which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
  • Leucocyte extract which ma be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
  • Bearberry extract which maybe present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
  • Licorice extract which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
  • Mulberry extract which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%.
  • a safe and effective amount of a desquamation active maybe added to the compositions of the present invention, more preferably from about 0.1% to about 10%, even more preferably from about 0.2% to about 5%, by weight of the composition.
  • Desquamation actives enhance the skin appearance benefits of the present invention.
  • One desquamation system that is suitable for use herein contains sulfhydryl compounds and zwitterionic surfactants and is described in U.S. Pat. No. 5,681,852, to Bissett, incorporated herein by reference.
  • Another desquamation system that is suitable for use herein contains salicylic acid and zwitterionic surfactants and is described in U.S. Pat. No. 5,652,228 to Bissett, incorporated herein by reference.
  • Zwitterionic surfactants such as described in these applications are also useful as desquamatory agents herein, with cetyl betaine being particularly preferred.
  • the necessary amounts of the cosmetic and dermatological adjuvants and additives can, based on the desired product, easily be determined by the skilled person.
  • the efficiency of bis-pantoyl-cystamine for use in accordance with the present invention can, e.g., be shown by its ability to inhibit melanin production in human primary melanocytes using the methods described below.
  • a mixture of bis-pantoyl- cystamine diastereomers as obtainable by the process described below in paragraph D. was used.
  • Normal human melanocytes were obtained from freshly excised foreskin of skin type II/III or IV- VI. Human melanocytes were maintained in 75cm 2 culture flasks in melanocyte growth medium M2 supplemented with 1% Pen/Step at 37°C in a water-saturated, 5% CO 2 in air atmosphere. Cultured melanocytes were placed in a 6-well plate at a density of 120.000 cells/well, 2-3 days precultivated and over 5 days treated with daily renewed agents at designated concentrations.
  • human melanocytes were cultured with the agents in designated concentrations in a 6-well plate as mentioned above Following the lapse of given experimental periods, the cells were harvested and then collected by centrifugation.
  • the amount of melanin produced for each well was quantified by assessing melanin released into the culture media.
  • the human melanocyte based assay for melanogenesis were done in a defined volume of colorless growth medium over 5 days.
  • the media from each well were transferred and the amount of melanin were quantified by reading the absorbance spectrum, esp. at 475nm or 530nm.
  • Tyrosinase activity using L-dopa as the substrate was assayed spectrophotometrically.
  • Tyrosinase reaction were performed with 0.1M Sodium phosphate buffer (pH 6.4) containing 5U commercial available mushroom tyrosinase, designated concentrations of L-dopa as the substrate in the presence or absence of agents like bis-pantoyl-cystamine or standart tyrosinase inhibitors as control.
  • the plates were incubated at 37°C for 10, 20 or 30min, respectively, and the absorbance was measured at 465nm in a microplate reader.
  • melanin content in human melanocyte culture was calculated in the absence or presence of different Bis-pantoyl cystamine concentrations.
  • estol 3650 (Glyceryl Myristate) 5.00 Lanette 16 (Cetyl Alcohol) 2.00 Amphisol A (Cetyl Phosphate) 2.00 Tegosoft M (Isopropyl Myristate) 10.00 Vitamine E Acetate (Tocopheryl Acetate) 0.50 Almond Oil 2.00 BHT 0.05 Phenonip (Phenoxyethanol & Methylparaben 8c 0.60 Ethylparaben & Propylparaben & Butylparaben & Isopropylparaben)
  • estol 3650 (Glyceryl Myristate) 5.00 Lanette 16 (Cetyl Alcohol) 2.00 Brij 72 (Steareth-2) 2.00 Brij 721 (Steareth-21) 2.00 Tegosoft M (Isopropyl Myristate) 10.00 Bisabolol 0.20 Vitamine E Acetate (Tocopheryl Acetate) 1.00 Almond Oil 2.00 BHT 0.05 Phenonip (Phenoxyethanol & Methylparaben 8c 0.60 Ethylparaben 8c Propylparaben 8c Butylparaben 8c Isopropylparaben)
  • estol 3650 (Glyceryl Myristate) 5.00
  • Lanette 16 (Cetyl Alcohol) 2.00
  • Phenonip (Phenoxyethanol ⁇ c Methylparaben ⁇ c 0.60
  • Myritol 318 (Caprylic/Capric Triglyceride) 5.00
  • Vitamine E Acetate (Tocopheryl Acetate) 1.00
  • Phenonip (Phenoxyethanol ⁇ c Methylparaben ⁇ c 0.60
  • Pemulen TR-1 (Acrylate/C10-30 Alkyl Acrylate 0.80 Crosspolymer)
  • Hyasol BT (Sodium Hyaluronate) 1.00
  • BHT Butylated Hydroxytoluene
  • Edeta BD (Disodium EDTA) 0.10
  • Phenonip (Phenoxyethanol ⁇ c Methylparaben ⁇ c 0.60
  • Carbopol 980 (Carbomer) 10.00
  • Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80 Crosspolymer)
  • Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80 Crosspolymer)
  • Hyasol BT (Sodium Hyaluronate) 1.00
  • Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80
  • Hyasol BT (Sodium Hyaluronate) 1.00
  • Parsol 1789 (Butyl Methoxydibenzoylmethane 1.50 Uvinul Titanium Dioxide (Titanium Dioxide) 3.00 Parsol MCX (Ethyl Hexylmethoxycinnamate) 4.00 Tegosoft TN (C12- 15 Alkyl Benzoate) " 8.00 Silicone 2503 Cosmetic Wax (Stearyl Dimethicone) 2.00 Cetyl Alcohol 1.00 Butylated Hydroxytoluene (BHT) 0.05 Estol GMM 3650 (Glyceryl Myristate) 4.00 Edeta BD (Disodium EDTA) 0.10 Phenonip (Phenoxyethanol ⁇ c Methylparaben ⁇ c 0.60 Ethylparaben 8c Propylparaben ⁇ c Butylparaben) AMPHISOL K (Potassium Cetyl Phosphate) 2.00
  • Myritol 318 (Caprylic/Capric Triglyceride) 7.00
  • Phenonip Phenoxyethanol ⁇ c Methylparaben ⁇ c 0.80 Ethylparaben ⁇ c Propylparaben ⁇ c Butylparaben AMPHISOL K (Potassium Cetyl Phosphate) 2.00
  • Carbopol ETD 2020 (Acrylate/C 10-30 Alkyl 0.30
  • Edeta BD (Disodium EDTA) 0.10
  • Lamepon S (Potassium Cocoyl Hydrolysed 5.00 Collagen)
  • Plantaren 1200 (Lauryl Glucoside) 5.00
  • Vitamine E Acetate (Tocopheryl Acetate) 0.30 Cremophor RH 40 (PEG-40 Hydrogenated Castor 2.00 Oil)

Abstract

The invention relates to topical compositions which comprise bis-pantoyl cystamine or a derivative thereof, and a vehicle conventionally used in topical compositions.

Description

COMPOSITIONS FOR SKIN LIGHTENING COMPRISING BIS-PANTOYL-CYSTAMINE
The present invention relates to compositions for skin lightening comprising bis-pantoyl- cystamine or derivatives thereof. More particularly, the present invention relates to topical compositions comprising bis-pantoyl-cystamine or derivatives thereof for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin. In another aspect, the present invention relates to the use of bis-pantoyl- cystamine or a derivative thereof in the manufacture of a topical composition for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin and to a method of lightening the skin, treating hyperpigmented skin disorders and preventing tanning of the skin which comprises topically administering bis-pantoyl-cystamine or a derivative thereof to the inflicted parts of the skin of a person in need of such treatment.
Skin lightening has been of concern to human beings for many years. In particular, the ability to remove hyper pigmentation, such as found in age spots, freckles or aging skin generally, is of interest to individuals to minimize skin blotchiness or desiring a uniform skin tone. Skin lightening in humans is also desired to lighten the natural color of their skin or to prevent of tanning after environmental factors like UV and leads to a more even skin tone.
The understanding of the chemical and enzymatic basis of melanogenesis is heavily documented. The color of human skin is determined by melanin, a biopolymer pigment manufactured by special dendritic cells known as melanocytes residing mostly between the basal cells of the epidermis. The melanocytes produce secretory granules, melanosomes, which produce the desired melanin. Melanogenesis occurs within the melanosome, and the melanin is later distributed to keratinocytes via the melanocytes dendrites and leads to a more or less pronounced tan or brown skin color.
The biochemical process is a cascade of biosynthesis where the key enzyme is called tyrosinase and triggers several steps in the formation of melanin from tyrosine. Melanin is the end product of an oxidative process in which tyrosine is converted with the aid of the enzyme tyrosinase via 3,4-dihydroxyphenylanlanine (dopa), dopaquinone, leucodopacrome, dopacrome, 5,6-dihydroxyindol and indole-5,6-quinone to give, finally, melanin. Although primary regulation of melanin production is via genetic controls, environmental factors may also play an important role in synthesis. Exposure to sunlight or other UV radiation can stimulate the melanocytes to produce more melanin, hence the so-called "tanning" reaction. Melanin production can also increase in response to hormone fluctuations associated with aging, child bearing or the use of birth-control pills. Normal pigmentation of the skin surface is uniform. Localized, excessive pigmentation can occur and such colorization is collectively referred to as hyper pigmentation. Hyper pigmentation encompasses a wide array of afflictions, all of which are accompanied by increased melanin production. Hyper pigmentation of the human skin may include skin blemishes or disorders including freckles, senile lentigo, liver spots, melasma, brown or age spots, sunburn pigmentation, post-inflammatory hyper pigmentation due to abrasion, burns, wounds, insect bites, dermatitis, and other similar small, fixed pigmented lesions.
From a cosmetic and dermatological standpoint, it may often be desirable to decolorize what is considered normally pigmented skin to increase "fairness" or to blend hyper pigmented regions into that of the surrounding normal skin.
The present invention thus comprises topical compositions, i.e. compositions for cosmetic as well as for dermatological, i.e., pharmaceutical, use which contain the active ingredient, bis-pantoyl-cystamine or a derivative thereof, in a vehicle that is conventionally used in cosmetic or topical dermatological compositions. The amount of bis-pantoyl-cystamine or derivative thereof in such compositions is about 0.005 % by weight to about 8.0 % by weight, preferably about 0.05% by weight to about 5.0 % by weight based on bis-pantoyl- cystamine and the total weight of the composition, respectively. . The treatment may extend to a period up to several monthsln general, a treatment for the duration of 6-8 weekswill suffice to achieve a substantial lightening effect. The compound bis-pantoyl-cystamine, (by systematical name : N,N'-(dithio-2,l- ethanediyl)bis(2,4-dihydrox-3,3-dimethyl) butanamide) which has the formula
(HO-CH2-C(CH3)2-C*HOH-CO-NH-CH2CH2-S-)2
contains two chiral centers as indicated by an asterisk. Therefore, bis-pantoyl-cystamine may exist in 3 isomeric forms with RR, RS and SS configurations. The isomer with RR configuration is known and has been described in the literature ( Boxer at al, J. Biol Chem., 1955, 217,541 Shimizu et al Chem Pharm Bull, 1970, 18, 838 .) The RR/SS diastereomeric pair and the RS (meso) isomer, and mixtures of RR, SS, RR/SS and RS are new and, as such, are also an object of the present invention. While all isomeric forms and their mixtures are intended for use in accordance with the invention, the new isomers and mixtures are preferred. Particularly preferred are the RR/SS diastereomeric pair, and the mixture composed of RR, RS, and SS isomers in a molar ratio of about 25:50:25 to about 30:40:30. They possess unexpected advantageous properties for manufacture, handling, and use.
The substances described are conveniently prepared by reaction of pantolactone with cystamine. When R-pantolactone is used, the RR isomer results which in pure form is found to be a very viscous oil. When S-pantolactone is used, the SS isomer results, which as the pure isomer is also a very viscous oil. These materials are somewhat difficult to handle due to their high viscosity even when warmed. Purification of such materials is normally more difficult than with crystalline solids.
When equal amounts of the RR and SS isomers are mixed there results a new substance, an RR/SS diasteromeric pair , which is a solid easily purified by crystallization.
When racemic pantolactone is used, there results a mixture composed of RR, RS, and SS isomers in a molar ratio of 25:50:25. Unexpectedly, this mixture can easily be crystallized to a white solid which can be further purified by recrystallization, e.g., from ethyl acetate or water. Such purification may result in a change of the RR, RS, and SS isomer molar ratio to about 30:40:30. For the purposes of the present invention, the preferred molar ratio in terms of the RS (meso) to RR/SS ratio is in the range from about 50:50 to about 30:70.
Cosmetic products require the highest standard of purity and safety because of contact to human skin, hair, and mucous membranes. Customers are particularly sensitive to color and odor of such products. Thus purification to the highest quality of this type products is essential. And ease of purification an advantage to manufacturing. Thus the RR or SS isomers can be used as hair care products provided specialized methods of purification are employed. The mixture of RR/SS and RS meso isomers offer an advantage is being easily purified by conventional chemical process techniques such as crystallization. Accordingly, for the purposes of the present invention the use of the mixture of RR/SS and RS meso isomers, and derivatives thereof, is preferred.
The term "derivative" as used herein denotes any compound that is obtained from bis- pantoyl-cystamine by modification of the hydroxy groups contained therein, particularly the terminal hydroxy groups, and which, while possessing the same or higher degree of lipophilicity than bis-pantoyl-cystamine exerts a similar activity as bis-pantoyl-cystamine. The making of lipophilic derivatives is a well known method by the person skilled in the art to achieve better skin delivery of a topically applied active ingredient. Examples of such derivatives are acylates, particularly acylates formed with aliphatic, aromatic or araliphatic carboxylic acids containing 2-20 carbon atoms, which may be saturated or unsaturated, and maybe substituted by, e.g. hydroxy groups, such as the mono- or di-acetate, propionate, butyrate, caproate, caprylate, caprate, laurate, myristate, lactate, 2- hydroxycaprylate, 2-hydroxycaprate, 2-hydroxylaurate, 2-hydroxymyristate, di-2-heptyl- undecanoate, and salicylate. Examples of acylates derived from unsaturated carboxylic acids are oleates and linoleates.
The compositions of the present invention can, e.g., be provided in the form of a lotion, a thickened lotion, a gel, a cream, a milk, a cleansing composition, an ointment, a powder or a solid tube stick and may optionally be packaged as an aerosol and may be provided in the form of a mousse, foam or a spray. They may be in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or microemulsion (in particular of O/W or W/O type, O/W/O or W/O/W-type), such as a cream or a milk, a vesicular dispersion, in the form of an ointment, a gel, a solid tube stick or an aerosol mousse. The emulsions can also contain anionic, nonionic, cationic or amphoteric surfactants.
The compositions of the invention also contain adjuvants and additives, which are conventionally used in cosmetic or dermatological compositions, such as preservatives/ antioxidants, fatty substances/ oils, water, organic solvents, silicones, thickeners, softeners, emulsifiers, additional sunscreens, antifoaming agents, moisturizers, skin penetration enhancers, vitamins, desquamation actives, skin soothing actives, fragrances, surfactants, cleansing agents, fillers, sequestering agents, anionic, cationic, nonionic or amphoteric polymers or mixtures thereof, propellants, acidifying or basifying agents, dyes, colorants, pigments or nanopigments, in particular UV screening agents suitable for providing a photoprotective effect by physically blocking out ultraviolet radiation, conventional skin lightening agents, or any other ingredients usually formulated into cosmetics, in particular for the production of skin lightening compositions, sunscreen compositions and anti- aging compositions.
According to embodiments of the invention, bis-pantoyl-cystamine or derivatives thereof is used in combination with one or more agents selected from UV screening agents, vitamin A or derivatives thereof, ascorbic acid or ascorbic acid derivatives, vitamin E or . derivatives thereof, a vitamin from the B complex, panthenol, phytantriol, bisabolol or derivatives thereof, Kojic acid or derivatives thereof, Arbutin or derivatives thereof, Hydroquinone or derivatives thereof, Genistein or derivatives thereof, Epigallocatechin Gallate or derivatives thereof, and Resveratrol or derivatives thereof, Phyllanthus Emblica fruit extract, Leucocyte extract, Bearberry extract, Licorice extract and Mulberry extract .
The term "UV screening agent" means a compound or composition that absorbs UV radiation in the range of about 320 nm to about 400 nm (UV-A) or in the range of about 280 nm to about 320 nm (UV-B). Such UV filters can be organic or inorganic. Organic sunscreens include dibenzoylmethane derivatives such as butyl methoxydibenzoylmethane (PARSOL 1789), benzylidene-cyanoacetates such as 4-mefhoxy-benzylidene-cyanoacetic acid n-hexyl ester, triazine derivatives such as 4,4'-(6-(bis(2-ethyl-hexyl)-amino)-s- triazine-2,4-diyl)-diresorcinol, anilinomethylene derivatives such as 2-(4-ethoxy-anilino- methylene)-propanedioic acid diethyl ester, camphor derivatives sich as 4-methyl benzylidene camphor (PARSOL 5000) and terephtalylidene-3,3'-dicamphor-10,10'-disul- fonic acid, benzimidazol derivatives such as 2,2'-( l,4-phenylen)-bis-lH-benzimidazol-4,6- disulfonic acid Na salt; cinnamates such as ethylhexyl methoxycinnamate (PARSOL MCX); salicylic acid derivatives such as ethylhexyl salicylate and homomenthyl salicylate; p-aminobenzoic acid derivatives such as p-dimethylaminobenzoic acid 2-ethylhexyl ester; benzophenone derivatives such as 2-hydroxy-4-methoxy-benzophenone, and 4-phenyl- benzophenone-2-carboxylic acid 2-ethylhexyl ester; anthranilates such as homomenthyl- N-acetylanthranilate and menthylanthranilate; acrylates such as 2-efhylhexyl-2-cyano-3,3- diphenylacrylate ((PARSOL 340); benzimidazole derivatives such 2-phenylbenzimidazole- 5-sulphonic acid (PARSOL HS); benzoxazole derivatives such as 2-phenyl-5-methyl- benzoxazole, malonate derivatives such as dimethico diethylbenzalmalonate (PARSOL SLX); triazine derivatives such as 2,4-Bis((4-(ethyl-hexylox)-2-hydroxy)-phenyi)-6-(4- methoxyphenyl)- l ,3,5-triazine (Tinosorb S - Ciba); benzotriazol derivatives such as 2,2'- Methylene-bis-(6(2H-benzotriazol-2-yl)-4-( l,l,3,3,-tetramethylbutyl)phenol) (Tinosorb M - Ciba), Uvinul T- 150 (BASF), UVASORB HEB (3V- Sigma). In preferred compositions the UV-A filter is selected from the group consisting of PARSOL 1789, 4,4'-(6-(bis(2- ethyl-hexyl)-amino)-s-triazine-2,4-diyl)-diresorcinol (Triazin), 2-(4-ethoxy- anilinomethylene)-propanedioic acid diethyl ester, and mixtures thereof, PARSOL MCX or PARSOL SLX.
Further examples of organic UV filters for use in the present invention are : Compounds as disclosed in European patent application No. 02015849.9 filed 16.7.2002 the contents of which are incorporated herein for reference, and which are characterized by the presence of one each of the structural elements (H3C)3-Si- (I) and -0-Si(CH3)3 (II), and 2-200 elements in arbitrary order selected from -0-Si(CH3)[CH(CH3)R1]- (Ilia), -O- Si(CH3)(CH2-CH2-R')- (Illb), -O-Si(CH3)[C(=CH2)R1]- (IIIc), and -O- Si(CH3)(CH=CH-R1)- (Hid) wherein R1 is a UV light absorbing group; and 2-200 elements in arbitrary order selected from Ilia, Illb, IIIc and Hid wherein R1 is hydrogen or a lipophilic group; and, optionally, 1-100 elements in arbitrary order selected from Ilia, Illb, IIIc and Illd wherein R is a group which is able to form ionogenic or hydrogen bonds, and, further optionally, 1-20 elements in arbitrary order of formula-0-SiH(CH3)-;
Compounds as disclosed in European patent application No. 02008419.0 filed 12.4.2002 the contents of which are incorporated herein for reference, which comprise a unit of the formula
Z-Si-O, (3-a)/2 wherein
a is 0, 1 or 2,
R1 is hydrogen, a saturated or unsaturated Cι-C3ohydrocarbon group or a trimethylsilyloxy group; and Z is an amino substituted hydroxybenzophenone of the formula
Figure imgf000008_0001
wherein
R3 and R4 independently are hydrogen, Cι-C20alkyl, C2-C2oalkenyl, C3-Cι0cycloalkyl or C3-Cιocycloalkenyl or R and R , together with the nitrogen atom they are bound to, form a 5 to 6 membered ring;
X is -O- or -NR5- wherein R5 is hydrogen, Cι-C2oalkyl, C2-C2oalkenyl, C3-C10cycloalkyl or C3-Cιocycloalkenyl; and
Y is a divalent C3-Cι2alkylene or alkenylene chain; and, optionally, a unit of the formula
,2
I b
Si-0 (4-b)/2 wherein
b is 0, 1, 2, 3; and
R2 is hydrogen, a saturated or unsaturated CrC30hydrocarbon group or a trimethylsilyloxy group;
Compounds as disclosed in European patent application No. 02002093.9 filed 12.2.2002 the contents of which are incorporated herein for reference, and which are of the general formulas
Figure imgf000008_0002
wherein m is 1 or 2; R and R" are identical or different electron-withdrawing groups, or one of R1 and R is hydrogen and the other of R and R is an electron-withdrawing group; R3, R4, R5, are R6 are, independently, hydrogen, alkyl or aryl; R3 and R5 and/ or R4, and R6 taken together with the carbon atoms to which they are attached, may form a 5 or 6 membered ring which optionally is substituted with one to four alkyl or alkoxy groups; X is a moiety R7 , when m is 1; and is alkylene or poly(oxyalkylene) when m is 2; and R7 is hydrogen, alkyl, alkoxyalkyl or aryl; and
Compounds as disclosed in European patent application No. 02014158.6 filed 25.6.2002 the contents of which are incorporated herein for reference, and which are of the general formula I
Figure imgf000009_0001
wherein R1 and R are, independently from each other, hydrogen; halogen; hydroxy; ( - C2o)-alkyl; (C2-C2o)-alkenyl; or (CrC2o)-alkoxy; X is oxygen or an imino group, optionally substituted with R1; R3 and R4 are, independently from each other, cyano; -COOR5; -COR6; -CONH2; -CONHR7; or -CONR8R9; R5, R6, R7, R8 and R9 are, independently from each other, hydrogen; (Cι-C2o)-alkyl, wherein one or more methylene groups are optionally replaced by one or more oxygens; (Ci-C o)-haloalkyl; (C2-C2o)-alkenyl, optionally substituted by tri-(Cι-C5)-alkylsilyl, triphenylsilyl or a group -Si [CH3]n[OSi(CH3)3]3_n, wherein n is 0, 1, 2 or 3.
A safe and effective amount of the organic sunscreen active is used, typically from about 1 wt.-% to about 20 wt.-%, more typically from about 2 wt.-% to about 10 wt.-%.
Other suitable sunscreen actives may also be inorganic sunscreens. Inorganic sunscreens useful herein include the following metallic oxides; titanium dioxide having an average primary particle size of from about 15 nm to about 100 am, zinc oxide having an average primary particle size of from about 15 nm to about 150 mu, zirconium oxide having an average primary particle size of from about 15 nm to about 150 nm, iron oxide having an average primary particle size of from about 15 nm to about 500 nm, and mixtures thereof. When used herein, the inorganic sunscreens are present in the amount of from about 0.1 wt.-% to about 20 wt.-%, preferably from about 0.5 wt.-% to about 10 wt.-%, more preferably from about lwt.-% to about 5 wt.-%.
Vitamin A acetate or palmitate which may be present in the skin care products in an amount from about 0.01 wt.-% to about 1.00 wt.-%. The term ascorbic acid derivative for use in accordance with the present invention may by any non-toxic, non skin-irritating water-soluble or oil-soluble ascorbic acid derivative. Example of such oil soluble derivatives are ascorbyl palmitate, ascorbyl tetraisopalmitate, ascorbyl linoleate, ascorbyl octanoate. Preferred are water soluble ascorbyl derivatives such as sodium ascorbyl phosphate, magnesium ascorbyl phosphate and ascorbyl glycoside. The amount of ascorbic acid derivative in the skin care product for use in accordance with the present invention is suitably in the range from about 0.1 wt.-% to about 5 wt.-%.
A vitamin E derivative for use in the present invention is tocopheryl acetate. Tocopheryl acetate may be present in the skin care products in an amount from about 0.05 wt.-% to about 5 wt.-%. Another vitamine E derivative of interest is tocopheryl linoleate. Tocopheryl linoleate may be present in the skin care composition in an amount from about 0.05 wt.-% to about 5 wt-%.
Examples of vitamins from the B complex for use in the present invention are vitamin B3, B6 and biotin. Vitamin B3 ma be present in the skin care products in an amount from about 0.01 wt.-% to about 1.00 wt.-%. Vitamin B6 maybe present in the skin care products in an amount from about 0.01 wt-% to about 1.00 wt.-%. Biotin ma be present in the skin care products in an amount from about 0.001 wt.-% to about 0.5 wt.-%.
Panthenol may be present in the skin care products in an amount from about 0.05 wt-% to about 5.00 wt.-%. Phytantriol ma be present in the skin care products in an amount from about 0.01 wt.-% to about 2.5 wt.-%. Bisabolol may be present in the skin care products in an amount from about 0.05 wt.-% to about 5.00 wt-%.
Further skin lightening agent which may be used in the present invention in combination with bis-pantoyl-cystamine are Kojic acid or derivatives thereof, which may be present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 5 wt-%;
Arbutin or derivatives thereof, which maybe present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 5 wt-%;
Hydroquinone or derivatives thereof, which may be present in the skin care products of the present invention in an amount from about 0.05 wt-% to about 2 wt-%;
Phyllanthus Emblica fruit extract (trade name: Emblica ), which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%; Leucocyte extract, which ma be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
Bearberry extract, which maybe present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%;
Licorice extract, which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%; and
Mulberry extract, which may be present in the skin care compositions of the present invention in an amount from 0.05 wt-% to about 3 wt-%.
A safe and effective amount of a desquamation active maybe added to the compositions of the present invention, more preferably from about 0.1% to about 10%, even more preferably from about 0.2% to about 5%, by weight of the composition. Desquamation actives enhance the skin appearance benefits of the present invention. One desquamation system that is suitable for use herein contains sulfhydryl compounds and zwitterionic surfactants and is described in U.S. Pat. No. 5,681,852, to Bissett, incorporated herein by reference. Another desquamation system that is suitable for use herein contains salicylic acid and zwitterionic surfactants and is described in U.S. Pat. No. 5,652,228 to Bissett, incorporated herein by reference. Zwitterionic surfactants such as described in these applications are also useful as desquamatory agents herein, with cetyl betaine being particularly preferred.
The necessary amounts of the cosmetic and dermatological adjuvants and additives can, based on the desired product, easily be determined by the skilled person.
The efficiency of bis-pantoyl-cystamine for use in accordance with the present invention can, e.g., be shown by its ability to inhibit melanin production in human primary melanocytes using the methods described below. In these tests, a mixture of bis-pantoyl- cystamine diastereomers as obtainable by the process described below in paragraph D. was used.
1. Human melanocyte based assay for melanogenesis
Normal human melanocytes were obtained from freshly excised foreskin of skin type II/III or IV- VI. Human melanocytes were maintained in 75cm2 culture flasks in melanocyte growth medium M2 supplemented with 1% Pen/Step at 37°C in a water-saturated, 5% CO2 in air atmosphere. Cultured melanocytes were placed in a 6-well plate at a density of 120.000 cells/well, 2-3 days precultivated and over 5 days treated with daily renewed agents at designated concentrations. In the case of stimulation we irradiated the melanocytes once per day over a period of 5 days with 2.5j/cm from a Philips Sunmobile as UV-A source in DMEM without phenolred, plus 0.2% Glucose and 50mM HEPES. Cells from one well were harvested and dissolved in IN NaOH with vigorous vortexing and 30min incubation in an ultra sound bath. Melanin contents were determined in the supernatant by measuring the absorption of cell lysated at 475nm and by adopting it to a standard curve made with the use of synthetic melanin.
2. Cell-Pellet assay
For this assay human melanocytes were cultured with the agents in designated concentrations in a 6-well plate as mentioned above Following the lapse of given experimental periods, the cells were harvested and then collected by centrifugation.
3. Melanin content in media
The amount of melanin produced for each well was quantified by assessing melanin released into the culture media. The human melanocyte based assay for melanogenesis were done in a defined volume of colorless growth medium over 5 days. The media from each well were transferred and the amount of melanin were quantified by reading the absorbance spectrum, esp. at 475nm or 530nm.
4. Tyrosinase assay
Tyrosinase activity using L-dopa as the substrate was assayed spectrophotometrically. Tyrosinase reaction were performed with 0.1M Sodium phosphate buffer (pH 6.4) containing 5U commercial available mushroom tyrosinase, designated concentrations of L-dopa as the substrate in the presence or absence of agents like bis-pantoyl-cystamine or standart tyrosinase inhibitors as control. The plates were incubated at 37°C for 10, 20 or 30min, respectively, and the absorbance was measured at 465nm in a microplate reader.
Results
1. Human melanocytes were following treatment collected by centrifiigation and photographed. Appearance of the pellets in the absence and presence after 5d treatment with different Bis-pantoyl cystamine concentrations is shown in the figure below.
Figure imgf000013_0001
Bis-pantoyl cystamine (Pantothiol) (mM)
2. As in the methology described melanin content in human melanocyte culture was calculated in the absence or presence of different Bis-pantoyl cystamine concentrations.
2.1. Depigmentation of Bis-pantoyl cystamine in melanocytes from skin type II/III without stimulation via UV-A irradiation.
Figure imgf000013_0002
2.2. Depigmentation of Bis-pantoyl cystamine in melanocytes from skin type V without stimulation via UV-A irradiation.
_ 20.00
>
10.00
0.00
.0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 Bis-pantoyl cystamine (Pantothiol) (raM)
2.3. Depigmentation of Bis-pantoyl cystamine in melanocytes from skin type IV after 2.5j/cm2 UV-A irradiation.
Figure imgf000014_0001
C
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4 Bis-pantoyl cystamine (Pantothiol) ( M)
3. The amount of melanin in the cell culture medium were quantified by reading the absorbance spectrum. We were not able to detect any melanin in the media after 8 days cultivation of melanocytes. Bis-pantoyl-cystamine as a diastereomeric mixture or enantiomeric pair can be obtained as follows:
A. Preparation of RR-bis-pantoyl-cystamine
36.8 g of R-pantolactone was melted in a 500 mL round bottom flask at 95 °C inner temperature using an oil bath. To the stirred colorless liquid there was added dropwise 21.2 g of cystamin base and 0.94 ml of butanol . After 24 hours of heating the brown sirupy solution was allowed to cool to below 80 °C, then 225 ml of ethylacetate was added dropwise over 20 min. After the addition of 0.6 g of activated charcaol the hot suspension filtered over diatomaceous earth and filter paper. The light yellow clear solution was allowed to cool over the course of 2 hours during which time an oil settled out. The solvent was removed by rotovacuum distillation at 75 °C and 40 mm to yield a yellowish brown oil of 32.0 g crude product. This was chromatographed on 500 g of silica gel using a 9:2 mixture of ethylacetate and ethanol The homogeneous fractions were evaporated, then dried by heating in vacuo at 70 °C and 0.25 mm for 40 hours to yield 18.4 g of RR-bis-pantoyl-cystamine as a glassy orange-coloured oil. HPLC analysis showed a purity of 95% with a diastereomer ratio of 3:96 of RS meso and
RR/SS isomers. ( The small amount of products of the S isomer results from S isomer in the R-pantolactone. ) This sample remained a glass on storage at room temperature for over 2 months. NMR data were consistent with the structure assigned.
B. Preparation of SS-bis-pantoyl-cystamine
2 g of S-pantolactone was melted at 95 C internal temperature in a round bottom flask 1.16 gof cystamin base was added dropwise followed by 0.05 ml of butanol and the mixture was stirred for 22 hours. The were added to the brown sirupy mixture
12 ml of ethyl acetate and 0. 03 g of activated charcoal, the mixture filtered through diatomaceous earth and paper, and the filtrate evaporated in vacuo. The resulting yellow oil was chromatographed on silica and the recovered product dried by heating at 70 °C at 0.25mm to constant weight. There was obtained 0.74 g of orange glass comprised of 94 % of SS-bis-pantoyl-cystamine along with 2 % of its RS meso isomer (by HPLC analysis). This substance did not crystallize on storage at room temperature for 2 months.
C. Preparation of the RR/SS bis-pantoyl-cystamine (enantiomeric pair) 208 mg of the RR isomer and 208 mg of the SS isomer were mixed and kept at room temperature under argon overnight during which the mixture crystallized. 170 mg of the mixture was recrystallized from 8 mL of methanol-ethyl acetate (3:5) to give 134 mg of beige crystals of RR/SS bis-pantoyl-cystamine (enantiomeric pair) melting point ca. 145 °C.
D. Preparation of mixture of RR/SS- and RS-bis-pantoyl-cystamine.
121.5 g of DL-pantolactone was melted in a 2.5 L round bottom flask at an inner temperature of 95 °C. To this there was added dropwise 73.7 of cystamin base and 1.0 g of n-butanol. The mixture was stirred and heated for 16 hours, then the resulting sirupy brown solution was cooled to below 80 °C and was added over 20 monutes 744 ml of ethyl acetate and 2.0 g of activated charcoal, then the mixture was filtered over a teflon membrane filter. The clear filtrate was allowed to cool over the course of 2 hours to room temperature during which at about 50 °C crystallization occurred. The mixture was allowed to stir at room temperature for 3 hours, cooled to 10°C, held for 30 minutes, then filtered, and the solids rinsed with 150 mlof ethyl acetate (10 °C ) After 12 hours drying at 50 °C at 4mm there were obtained 165.8 g of beige solids consisting of 96 % by weight of a mixture of diastereomers of bis-pantoyl-cystamine. HPLC analysis showed this to be composed of a mixture of 41 % RS- isomer with 56% of the RR/SS-enantiomeric pair.
The following examples, which are to construed in a non-limitative manner, illustrate the preparation of a number of effective formulations of the invention.
Example 1
Skin Lightening Cream (O/W)
Ingredients % (w/w)
A) Estol 3650 (Glyceryl Myristate) 5.00 Lanette 16 (Cetyl Alcohol) 2.00 Amphisol A (Cetyl Phosphate) 2.00 Tegosoft M (Isopropyl Myristate) 10.00 Vitamine E Acetate (Tocopheryl Acetate) 0.50 Almond Oil 2.00 BHT 0.05 Phenonip (Phenoxyethanol & Methylparaben 8c 0.60 Ethylparaben & Propylparaben & Butylparaben & Isopropylparaben)
B) Tris (Tromethamine) 0.90
C) Water Ad 100 EDETA BD (Disodium EDTA) 0.10 Propylene Glycol 5.00 Transcutol (Ethoxydiglycol) 10.00 Bis-pantoyl-cystamine 2.00
D) Sepigel 305 (Polyacrylamide & C13-14 Isoparaffin 8c 2.00 Laureth-7)
E) Triethanolamine q.s.
Example 2
Skin Lightening Cream (O/W)
Ingredients % (w/w)
A) Estol 3650 (Glyceryl Myristate) 5.00 Lanette 16 (Cetyl Alcohol) 2.00 Brij 72 (Steareth-2) 2.00 Brij 721 (Steareth-21) 2.00 Tegosoft M (Isopropyl Myristate) 10.00 Bisabolol 0.20 Vitamine E Acetate (Tocopheryl Acetate) 1.00 Almond Oil 2.00 BHT 0.05 Phenonip (Phenoxyethanol & Methylparaben 8c 0.60 Ethylparaben 8c Propylparaben 8c Butylparaben 8c Isopropylparaben)
B) Water Ad 100 EDETA BD (Disodium EDTA) 0.10 Propylene Glycol 10.00 Sodium Ascorbyl Phosphate 1.00 Arbutin 1.00 D-Panthenol 0.50 Niacinamide 0.20 Salicylic acid 0.50 Bis-pantoyl-cystamine 1.00
C) Sepigel 305 (Polyacrylamide 8c C13-14 Isoparaffin 8c 2-00
Laureth-7)
D) Triethanolamine q.s.
Example 3
Skin lightening cream with UV protection (indicative
SPF: 8, O/W) Ingredients % (w/w)
A) Estol 3650 (Glyceryl Myristate) 5.00 Lanette 16 (Cetyl Alcohol) 2.00
Brij 72 (steareth-2) 2.00
Brij 721 ( steareth-21) 2.00
Tegosoft M (Isopropyl Myristate) 10.00
BHT 0.05
Ascorbyl Palmitate 0.50
Parsol 1789 (Butyl Methoxydibenzoylmethane) 1.00
Parsol MCX (Ethyl Hexylmefhoxycinnamate 2.00
Eusolex OS (Octyl Salicylate) 2.00
Phenonip (Phenoxyethanol δc Methylparaben δc 0.60
Ethylparaben δc Propylparaben δc Butylparaben &
Isopropylparaben)
B) Water Ad 100
EDETA BD (Disodium EDETA) 0.10
Bis-pantoyl-cystamine 2.00
Propyleneglycol 8.00
C) S Seeppiiggeell 2 2..0000
D) T Trriieetthhaannoollaammiinnee q q..ss..
Example 4
Skin Lightening Cream
(W/O)
Ingredients % (w/w)
A) Cremophor WO7 (PEG-7 Hydrogenated Castor Oil) 6.00
Elfacos ST 9 (PEG-45/Dodecyl Glycol Copolymer) 2.00
Myritol 318 (Caprylic/Capric Triglyceride) 5.00
Lunacera M (Micro wax) 2.00
Paraffin Oil 10.00
Resveratrol 0.50
Phytantriol 0.10
Vitamine E Acetate (Tocopheryl Acetate) 1.00
Jojoba Oil 5.00
BHT 0.05
Phenonip (Phenoxyethanol δc Methylparaben δc 0.60
Ethylparaben δc Propylparaben δc Butylparaben δc Isopropylparaben)
B) Water Ad 100
EDETA BD (Disodium EDTA) 0.10
D-Panthenol 0.50
Propylene Glycol 5.00
Kojic Acid 1.00
Bis-pantoyl-cystamine 1.00
Example 5
Skin Lightening Gel
Ingredients % (w/w)
A) Pemulen TR-1 (Acrylate/C10-30 Alkyl Acrylate 0.80 Crosspolymer)
Biotin 0.01
Water Ad 100
B) EDETA BD (Disodium EDTA) 0.10
D- Panthenol 0.20
Hyasol BT (Sodium Hyaluronate) 1.00
Euxyl K 400 (Methyldibromo Glutaronitrile δc 0.20
Phenoxyethanol)
C) NaOH (30%o) 1.00
D Water 12.00
Transcutol (Ethoxydiglycol) 10.00
Propylene Glycol 5.00
Epigallocatechin Gallate 0.50
Genistein 0.10
Niacinamide 0.50
Emblica (Phyllanthus Emblica fruit extract) 0.50
Hydroquinone 0.20
Bis-pantoyl-cystamine 2.00
E) Citric Acid (10%) q.s.
Example 6
Skin Lightening Lotion Ingredients % (w/w)
A) Water Ad 100 Propylene Glycol 5.00
Bis-pantoyl-cystamine 1.00
D-Panthenol 0.50
Sodium PCA 0.25
Ethanol 10.00
B) Citric Acid (10%) q.s.
Example 7
Skin lightening cream with UV protection
(indicative SPF: 8, O/W)
Ingredients % (w/w)
A ) ι PARSOL SLX (Dimethico Diethylbenzalmalonate) 8.00
Uvinul Titanium Dioxide (Titanium Dioxide) 2.00
Tegosoft TN (C12-15 Alkyl Benzoate) 5.00
Silicone 2503 Cosmetic Wax (Stearyl Dimethicone) 2.00
Cetyl Alcohol 1.00
Butylated Hydroxytoluene (BHT) 0.05
Estol GMM 3650 (Glyceryl Myristate) 4.00
Edeta BD (Disodium EDTA) 0.10
Phenonip (Phenoxyethanol δc Methylparaben δc 0.60
Ethylparaben δc Propylparaben δc Butylparaben)
AMPHISOL K (Potassium Cetyl Phosphate) 2.00
B) Water deionized Ad 100
Carbopol 980 (Carbomer) 10.00
Bis-pantoyl-cystamine 1.00
Propylene Glycol 5.00
C) KOH sol. 10% 0.50
Example 8
Skin Lightening Gel
Ingredients % (w/w)
A) Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80 Crosspolymer)
Water Ad 100
B) EDETA BD (Disodium EDTA) 0.10
D- Panthenol 0.10 Hyasol BT (Sodium Hyaluronate) 1.00
Euxyl K 400 (Methyldibromo Glutaronitrile δc 0.20
Phenoxyethanol)
C) NaOH (30%>) 1.00
D Water 12.00
Transcutol (Ethoxydiglycol) 10.00
Propylene Glycol 5.00
Melawhite (Water and Leucocyte extract) 1.00
Kojic Acid 0.50
Niacinamide 0.50
Hydroquinone 0.50
Bis-pantoyl-cystamine 1.00
E) Citric Acid (10%) q.s.
Example 9
Skin Lightening Gel
Ingredients % (w/w)
A) Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80 Crosspolymer)
Biotin 0.01
Water Ad 100
B) EDETA BD (Disodium EDTA) 0.10
D- Panthenol 0.10
Hyasol BT (Sodium Hyaluronate) 1.00
Euxyl K 400 (Methyldibromo Glutaronitrile δc 0.20
Phenoxyethanol )
C) NaOH (30%) 1.00
D Water 12.00
Transcutol (Ethoxydiglycol) 10.00
Propylene Glycol 5.00
Melfade (Water and Glycerin and Bearberry extract) 1.00
Kojic Acid 0.50
Niacinamide 0.50
Bis-pantoyl-cystamine 1.00
E) Citric Acid (10%) q.s. Example 10
Skin Lightening Gel
Ingredients % (w/w)
A) Pemulen TR-1 (Acrylate/ClO-30 Alkyl Acrylate 0.80
Crosspolymer)
Water Ad 100
B) EDETA BD (Disodium EDTA) 0.10
D- Panthenol 0.10
Hyasol BT (Sodium Hyaluronate) 1.00
Euxyl K 400 (Methyldibromo Glutaronitrile δc 0.20
Phenoxyethanol)
C) NaOH (30%) 1.00
D Water 12.00
Transcutol (Ethoxydiglycol) 5.00
Propylene Glycol 10.00
Licorice extract 0.50
Mulberry extract 0.50
Kojic Acid 0.50
Niacinamide 0.50
B is -pantoyl- cystamine 0.50
E) Citric Acid (10%) q.s.
Example 11
Skin Lightening Gel
Ingredients % (w/w)
A) Carbopol ETD 2020 (Carbomer) 0.80
Water Ad 100
Panthenol 0.50
Niacinamide 0.10
B) NaOH (30%) 0.50
C) Ethanol 35.00
Propylene Glycol 8.00
Bis-pantoyl-cystamine diacetate 2.00 Example 12
Skin lightening cream with UV protection (indicative SPF: 8, O/W)
Ingredients % w/ w
A ) Parsol 1789 (Butyl Methoxydibenzoylmethane 1.50 Uvinul Titanium Dioxide (Titanium Dioxide) 3.00 Parsol MCX (Ethyl Hexylmethoxycinnamate) 4.00 Tegosoft TN (C12- 15 Alkyl Benzoate) " 8.00 Silicone 2503 Cosmetic Wax (Stearyl Dimethicone) 2.00 Cetyl Alcohol 1.00 Butylated Hydroxytoluene (BHT) 0.05 Estol GMM 3650 (Glyceryl Myristate) 4.00 Edeta BD (Disodium EDTA) 0.10 Phenonip (Phenoxyethanol δc Methylparaben δc 0.60 Ethylparaben 8c Propylparaben δc Butylparaben) AMPHISOL K (Potassium Cetyl Phosphate) 2.00
B) Water deionized Ad 100 Carbopol 980 (Carbomer) 10.00 Bis-pantoyl-cystamine 2.00 Propylene Glycol 5.00
C) KOH sol. 10%) 0.50
Example 13
Skin lightening cream with UV protection (indicative SPF: 10, O/W) Ingredients % w / w
A ) PARSOL SLX (Polysilicone 15) 6.00
PARSOL 1789 (Butyl Methoxydibenzoylmethane) 2.00
Parsol MCX (Ethyl Hexylmethoxycinnamate) 4.00
Softisan 100 (Hydrogenated Coco-Glycerides) 2.00
Glyceryl Myristate 4.00
Myritol 318 (Caprylic/Capric Triglyceride) 7.00
Cosmacol ESI (Tridecyl Salicylate) 8.00
VITAMIN E ACETATE (Tocopheryl Acetate) 0.50
Phenonip (Phenoxyethanol δc Methylparaben δc 0.80 Ethylparaben δc Propylparaben δc Butylparaben AMPHISOL K (Potassium Cetyl Phosphate) 2.00
B ) Deionized water ad 100
1,2-Propylene Glycol (Propylene Glycol) 5.00
Carbopol ETD 2020 (Acrylate/C 10-30 Alkyl 0.30
Acrylate Crosspolymer)
Edeta BD (Disodium EDTA) 0.10
C ) KOH 10% sol.( Potassium Hydroxide) 1.60
D ) STAY-C 50 (Sodium Ascorbyl Phosphate) 1.00
Bis-pantoyl-cystamine 2.00
Deionized water 3.00
E) Retinyl Palmitate 0.50
VITAMIN E (Tocopherol) 0.10
Example 14
Skin lightening liquid soap
Ingredients % w / w
A ) Texapon NSO (Sodium Laureth Sulfate) 40.00
Tego Betain L7 (Cocamidopropyl Betaine) 10.00
Lamepon S (Potassium Cocoyl Hydrolysed 5.00 Collagen)
Plantaren 1200 (Lauryl Glucoside) 5.00
Cetiol HE (PEG-7 Glyceryl Cocoate) 3.00
Preservative q.s.
B ) Polymer JR 400 ( Polyquaternium- 10) 0.20 Water (Aqua) Ad 100 Panthenol 75 L (Panthenol) 0.40 Bis-pantoyl-cystamine 1.00 EDETA BD (Disodium EDTA) 0.10
C) Vitamine E Acetate (Tocopheryl Acetate) 0.30 Cremophor RH 40 (PEG-40 Hydrogenated Castor 2.00 Oil)
D) Sodium Chloride 1.00

Claims

What is claimed is:
1. Topical compositions which comprise bis-pantoyl-cystamine or a derivative thereof, and a vehicle conventionally used in topical compositions.
2. A composition as in claim 1 wherein the bis-pantoyl-cystamine is selected from at least one of RR-, SS-, RS (meso)- and RR/SS- bis-pantoyl-cystamine.
3. A composition as in claim 1 wherein the bis-pantoyl-cystamine is the enantiomeric pair, RR/SS-bis-pantoyl-cystamine, or R,S- (meso-) bis-pantoyl-cystamine, or mixtures thereof.
4. A composition as in claim 1 wherein the bis-pantoyl-cystamine is the diastereomeric mixture of RR/SS-bis-pantoyl-cystamine and R,S- (meso-) bis-pantoyl-cystamine wherein the molar ratio of RS(meso) : RR/SS is within the range from about 50:50 to about 30:70.
5. A composition as in any one of claims 1-4, wherein bis-pantoyl-cystamine is present in amount from 0.05 to 5.00 wt-%
6. A composition as in any one of claims 1-4, wherein bis-pantoyl-cystamine-diacetate is present in amount from 0.05 to 5.00 wt-%
7. A composition as in any one of claims 1-6 for cosmetic and pharmaceutical use, for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin.
8. A composition as in claim 7 which is a cream, a gel, an ointment, a lotion, a tincture, a spray, a mousse, a cleansing composition or a foam.
9. A composition according to any one of claims 1-8 comprising bis-pantoyl-cystamine or a derivative thereof in combination with one or more agents selected from UV screening agents, vitamin A or derivatives thereof, ascorbic acid or ascorbic acid derivatives, vitamin E or derivatives thereof, a vitamin from the B complex, panthenol, phytantriol, bisabolol or derivatives thereof, Kojic acid or derivatives thereof, Arbutin or derivatives thereof, hydroquinone or derivatives thereof, Genistein or derivatives thereof, Epigallocatechin gallate or derivatives thereof, Resveratrol or derivatives thereof, Phyllanthus Emblica fruit extract, Leucocyte extract, Bearberry extract, Licorice extract and Mulberry extract .
10. A composition according to claim 9 wherein the organic sunscreen is selected from the group consisting of butylmethoxydibenzoyl ethane, 2-(4-ethoxy-anilinomethylene)- propanedioic acid diethyl ester, ethylhexylmethoxycinnamate, ethylhexyl salicylate, octocrylene, 2-phenylbenzimidazole-5-sulphonic acid, dimethico diethylbenzalmalonate, 2,4-bis((4-(ethyl-hexyloxy)-2-hydroxy)-phenyl)-6-(4-methoxyphenyl)-l,3,5-triazine, and 2,2'-methylene-bis-(6(2H-benzotriazol-2-yl)-4-(l,l,3,3,-tetramethylbutyl)phenol)
11. A composition according to claim 9 wherein the inorganic sunscreen is selected from the group consisting of titanium dioxide and zinc oxide.
12. The use of bis-pantoyl-cystamine or a derivative thereof in the manufacture of a topical composition for lightening of the skin, for the treatment of hyperpigmented skin disorders and for preventing tanning of the skin.
13. The use in accordance with claim 12 wherein the bis-pantoyl-cystamine is selected from at least one of RR-, SS-, RS (meso)- and RR/SS- bis-pantoyl-cystamine.
14. The use in accordance with claim 12 wherein the bis-pantoyl-cystamine is the enantiomeric pair, RR/SS-bis-pantoyl-cystamine, or R,S- (meso-) bis-pantoyl-cystamine, or mixtures thereof.
15. The use in accordance with claim 12 wherein the bis-pantoyl-cystamine is the diastereomeric mixture of RR/SS-bis-pantoyl-cystamine and R,S- (meso-) bis-pantoyl- cystamine wherein the molar ratio of RS(meso) : RR/SS is within the range from about 50:50 to about 30:70.
16. The use in accordance with any one of claims 12-15, wherein bis-pantoyl-cystamine is present in amount from 0.05 to 5.00 wt-%
17. The use in accordance with any one of claims 12-15, wherein bis-pantoyl-cystamine- diacetate is present in amount from 0.05 to 5.00 wt-%.
18. A method of lightening the skin, treatment of hyperpigmented skin disorders, and preventing tanning of the skin, which comprises topically administering to a person in need of such treatment an effective amount of bis-pantoyl-cystamine or a derivative thereof.
PCT/EP2003/010702 2003-01-13 2003-09-25 Compositions for skin lightening comprising bis-pantoyl-cystamine WO2004062635A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003267413A AU2003267413A1 (en) 2003-01-13 2003-09-25 Compositions for skin lightening comprising bis-pantoyl-cystamine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03000721 2003-01-13
EP03000721.5 2003-01-13

Publications (1)

Publication Number Publication Date
WO2004062635A1 true WO2004062635A1 (en) 2004-07-29

Family

ID=32695589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/010702 WO2004062635A1 (en) 2003-01-13 2003-09-25 Compositions for skin lightening comprising bis-pantoyl-cystamine

Country Status (2)

Country Link
AU (1) AU2003267413A1 (en)
WO (1) WO2004062635A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039262A1 (en) * 2005-09-30 2007-04-12 Dsm Ip Assets B.V. Novel compositions containing polyphenols
WO2008110268A1 (en) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Cosmetic compositions
EP2522335A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and sodium-ascorbyl-phophate
EP2522329A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and arbutin
EP2522328A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and ascorbyl-2-glucoside
EP2522332A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and magnesium-ascorbyl-phosphate
EP2522331A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and niacinamide
EP2522330A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and an edelweiss extract
WO2013104526A1 (en) 2012-01-09 2013-07-18 Dsm Ip Assets B.V. Use of danielone and derivatives thereof in skin care
CN103932954A (en) * 2014-05-21 2014-07-23 张贺 Cosmetic for whitening and tendering skin and fining pores and preparation method thereof
WO2017190073A1 (en) * 2016-04-29 2017-11-02 Patel Purvisha All-in-one skin-brightening formulations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749719A (en) * 1983-09-21 1988-06-07 Sogo Pharmaceutical Company Limited Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749719A (en) * 1983-09-21 1988-06-07 Sogo Pharmaceutical Company Limited Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS; ; AN: 1960:129522 CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 April 2001 (2001-04-22), ARIYAMA, H., KIMURA, S.: "Pantothenic acid antagonist", XP002264999 *
DATABASE CAPLUS; AN 1983:554225 CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 May 1984 (1984-05-12) *
FRANCHI, JOCELYNE ET AL.: "Depigmenting effects of calcium D-pantetheine-S-sulfonate on human melanocytes", PIGMENT CELL RESEARCH, vol. 13, 2000, pages 165 - 171, XP002264942 *
JOURNAL OF VITAMINOLOGY, vol. 6, 1960, ISSN: 0022-5398, pages 52 - 61 *
QIU, LING ET AL.: "Inhibition of melanin synthesis by cystamine in human melanoma cells", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 114, no. 1, January 2000 (2000-01-01), pages 21 - 27, XP002264941 *
SHIMUZU, MASAO ET AL.: "Investigations on panthothenic acid and its related compounds", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 18, no. 4, 1970, pages 838 - 841, XP008025764 *
WITTWER, CARL.T. ET AL.: "Purification and Properties of a Pantethein-hydrolyzing Enzyme from Pig Kidney", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 16, 25 August 1983 (1983-08-25), pages 9733 - 9738, XP002264940 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039262A1 (en) * 2005-09-30 2007-04-12 Dsm Ip Assets B.V. Novel compositions containing polyphenols
WO2008110268A1 (en) * 2007-03-12 2008-09-18 Dsm Ip Assets B.V. Cosmetic compositions
EP2522335A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and sodium-ascorbyl-phophate
EP2522329A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and arbutin
EP2522328A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and ascorbyl-2-glucoside
EP2522332A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and magnesium-ascorbyl-phosphate
EP2522331A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and niacinamide
EP2522330A1 (en) 2011-05-09 2012-11-14 DSM IP Assets B.V. Use of resveratrol and an edelweiss extract
WO2013104526A1 (en) 2012-01-09 2013-07-18 Dsm Ip Assets B.V. Use of danielone and derivatives thereof in skin care
CN103932954A (en) * 2014-05-21 2014-07-23 张贺 Cosmetic for whitening and tendering skin and fining pores and preparation method thereof
WO2017190073A1 (en) * 2016-04-29 2017-11-02 Patel Purvisha All-in-one skin-brightening formulations

Also Published As

Publication number Publication date
AU2003267413A1 (en) 2004-08-10

Similar Documents

Publication Publication Date Title
KR101737662B1 (en) 2-phenyl-1,2,3-benzotriazoles for uv radiation absorbance
WO2004062635A1 (en) Compositions for skin lightening comprising bis-pantoyl-cystamine
EP1893207B1 (en) Use of substituted piperazine derivatives and morpholine derivatives
US6395260B1 (en) Topical cosmetic compositions comprising benzaldoximes
JP2009526125A (en) UV filter capsules containing amino-substituted hydroxybenzophenone
WO2009021589A1 (en) Tyrosinase inhibitors
US8906351B2 (en) 2,2′-furoin derivatives and use thereof to light skin
US20030072725A1 (en) Topical cosmetic agents containing 2-hydrazino-1,3 -heteroazoles
US7981899B2 (en) Use of compatible solutes for inhibiting the release of ceramides
WO2007051596A1 (en) Novel retinyl biotinates and use thereof
JP2019509301A (en) Medicine
EP1286654A1 (en) Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reactions of the skin
KR20140034255A (en) Extracts from eugenia uniflora
US20030049287A1 (en) Catechol oximes and their use in cosmetic and dermatological preparations
KR102211261B1 (en) C-xyloside compounds, compositions and use thereof to depigment the skin
WO2009089880A1 (en) Preparation containing chromane-2-one derivatives
EP1890672B1 (en) Use of chromone derivatives
US20210077370A1 (en) Use of compositions comprising dihydroxyacetone for the protection of skin or hair against infrared irradiation
JPH0848621A (en) Skin whitening cosmetic
DE102011109522A1 (en) Extracts of Tradescantia virginiana
KR20090131737A (en) Skin lightening composition
WO2007012379A2 (en) Use of 3-hydroxycoumarin derivatives
DE102010051689A1 (en) Dihydroxyfumaric acid derivatives and their use for skin lightening
KR20090131736A (en) Composition for improving skin wrinkle
DE10025557A1 (en) Prophylaxis and/or treatment of skin inflammatory reactions caused by noxious agents and/or foreign organisms, especially UV radiation, by topical administration of 1-(2-hydroxyphenyl)-alkan-1-one oxime derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP